ANDA 88804, held by Hospira. Trimethobenzamide Hydrochloride.
As of Nov 21, 2026, ANDA 88804 (Trimethobenzamide Hydrochloride), held by Hospira, was first approved by FDA on Apr 3, 1987, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 3, 1987 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Trimethobenzamide Hydrochloride100MG/ML · injectable;injection | Trimethobenzamide Hydrochloride | Discontinued |
| Feb 14, 2001 | Supplement 9Manufacturing | Approved | None posted |
| Sep 5, 2000 | Supplement 8Manufacturing | Approved | None posted |
| Jan 16, 1997 | Supplement 7Manufacturing | Approved | None posted |
| Dec 22, 1995 | Supplement 6Manufacturing | Approved | None posted |
| Mar 26, 1990 | Supplement 4Manufacturing | Approved | None posted |
| Jan 3, 1990 | Supplement 3Manufacturing | Approved | None posted |
| Oct 17, 1988 | Supplement 2Labeling | Approved | None posted |
| Apr 3, 1987 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters